Skip to main content

The negative reception afforded



big first quarter shows that it remains unsafe to buy healthcare in this market, Jim Cramer said on


"Stop Trading!" segment Wednesday.

Prior to Tuesday's report, Genentech shares lost about $10 due to concerns about Avastin. "We find out Avastin is booming, but now we don't like Rituxan and Tarceva," Cramer said. "It's too hard when it comes to healthcare. I think Genentech's a buy, but I can't believe how negative people are."

"People are so hung up on mineral stocks and metal benders that they just don't have enough money to buy the healthcare stocks that people are throwing away."

Morgan Stanley;s praise for


(GILD) - Get Free Report

sent the stock up a paltry 70 cents Wednesday. "I regard that as a disappointment," Cramer said. "Morgan Stanley actually knows what they're doing."

On the positive side, Cramer believes


(IR) - Get Free Report

should be performing as well as peers


(CAT) - Get Free Report



(DE) - Get Free Report



(HON) - Get Free Report

is "about to step up to the fore," although people were left "yawning" by Wednesday's dividend hike by

United Tech

(UTX) - Get Free Report


The problem is that with gold and minerals going up, investors are worried other sectors must come down, Cramer said. "It's very zero sum."

Cramer lamented the muted response to


(MDT) - Get Free Report

$2.5 billion buyback, which he compared to


(AMGN) - Get Free Report

repurchase last month. "No one notices."

At the time of publication, Cramer had no positions in the stocks mentioned.

Jim Cramer is a director and co-founder of He contributes daily market commentary for's sites and serves as an adviser to the company's CEO. Outside contributing columnists for and, including Cramer, may, from time to time, write about stocks in which they have a position. In such cases, appropriate disclosure is made. To see his personal portfolio and find out what trades Cramer will make before he makes them, sign up for

Action Alerts PLUS. Listen to Cramer's RealMoney Radio show on your computer; just click

here. Watch Cramer on "Mad Money" at 6 p.m. ET weeknights on CNBC. Click

here to order Cramer's latest book, "Real Money: Sane Investing in an Insane World," click

here to get his second book, "You Got Screwed!" and click

here to order Cramer's autobiography, "Confessions of a Street Addict." While he cannot provide personalized investment advice or recommendations, he invites you to send comments on his column by

clicking here. has a revenue-sharing relationship with Traders' Library under which it receives a portion of the revenue from Traders' Library purchases by customers directed there from